These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
841 related articles for article (PubMed ID: 26911584)
21. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639 [TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. Boeder S; Edelman SV Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593 [TBL] [Abstract][Full Text] [Related]
24. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524 [TBL] [Abstract][Full Text] [Related]
25. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus. Yale JF; Xie J; Sherman SE; Garceau C Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664 [TBL] [Abstract][Full Text] [Related]
26. Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis. Chen MB; Wang H; Zheng QH; Xu HL; Cui WY Medicine (Baltimore); 2021 Jan; 100(1):e24101. PubMed ID: 33429775 [TBL] [Abstract][Full Text] [Related]
27. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. Lingvay I Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871 [TBL] [Abstract][Full Text] [Related]
28. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC; Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456 [TBL] [Abstract][Full Text] [Related]
29. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients. Babar M; Hussain M; Ahmad M; Akhtar L J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526 [TBL] [Abstract][Full Text] [Related]
30. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis. Wang H; Yang J; Chen X; Qiu F; Li J Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143 [TBL] [Abstract][Full Text] [Related]
31. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Cefalu WT; Leiter LA; Yoon KH; Arias P; Niskanen L; Xie J; Balis DA; Canovatchel W; Meininger G Lancet; 2013 Sep; 382(9896):941-50. PubMed ID: 23850055 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis. Zhuang Y; Song J; Ying M; Li M Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755 [TBL] [Abstract][Full Text] [Related]
35. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Hemmingsen B; Krogh J; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2016 Apr; 4(4):CD012106. PubMed ID: 27101360 [TBL] [Abstract][Full Text] [Related]
36. Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy. Polidori D; Capuano G; Qiu R Diabetes Obes Metab; 2016 Apr; 18(4):348-54. PubMed ID: 26661906 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Liakos A; Karagiannis T; Athanasiadou E; Sarigianni M; Mainou M; Papatheodorou K; Bekiari E; Tsapas A Diabetes Obes Metab; 2014 Oct; 16(10):984-93. PubMed ID: 24766495 [TBL] [Abstract][Full Text] [Related]
38. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570 [TBL] [Abstract][Full Text] [Related]
39. Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. Blonde L; Patel C; Wu B; Chen YW; Pericone CD; Bookhart B Adv Ther; 2021 Jan; 38(1):594-606. PubMed ID: 33180317 [TBL] [Abstract][Full Text] [Related]
40. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Reed JW Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]